RxDoctor Payments Data

Brenda Knowles

Nurse Practitioner · Chattanooga, TNNPI 1689029837

Payments from drug & device makers

$7,724in general payments, 2019–2025

Across 443 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$900
  • Pfizer$769
  • Lundbeck LLC$412
  • Biohaven Pharmaceutical Holding Company Ltd.$264
  • UCB, Inc.$257
  • plus $2K from 32 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$7,55298%
  • Education$1562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,724 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$89,387
Medicare patients
108
Services billed
10,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate110$182,674
Emgality PenGalcanezumab-Gnlm104$73,098
UbrelvyUbrogepant57$64,704
QuliptaAtogepant33$39,207
Emgality SyringeGalcanezumab-Gnlm15$18,609
Aimovig AutoinjectorErenumab-Aooe12$13,093
ZavzpretZavegepant Hcl11$11,334
XareltoRivaroxaban14$9,949
Levetiracetam51$1,052
Gabapentin44$803
Rosuvastatin Calcium23$456
Topiramate48$358
Carbidopa-LevodopaCarbidopa/Levodopa20$263
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine47$251
Propranolol Hcl14$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret$769$194,008121 claims
AbbVieUbrelvy, Qulipta$2,683$103,91190 claims
Johnson & JohnsonXarelto$140$9,94914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →